Onego Bio and Sigma Foods Enter Collaboration to Strengthen Egg Protein Innovation and Supply Resilience
5.3.2026 16:00:00 CET | Business Wire | Press release
Onego Bio, a food ingredient company producing non-animal egg protein, and Sigma Foods ("SIGMA"), a leading multinational food company, have entered into a collaboration agreement to evaluate the functionality and commercial potential of Bioalbumen®, a non-animal egg protein made with using precision fermentation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305756400/en/
The partnership focuses on advancing ingredient innovation while addressing urgent challenges in today’s egg supply chain—including volatility, rising prices, and avian flu-related disruptions. Bioalbumen® offers a shelf-stable, animal-free alternative that delivers the same functional, nutritional, and sensory performance as traditional eggs, while helping safeguard supply continuity for food manufacturers.
Additionally, this collaboration supports Sigma’s commitment to offering safe, nutritious, and high-quality food, while driving science-based innovation through responsible ingredient sourcing. “At Sigma Foods, we are committed to delivering high-quality products in a sustainable and secure way,” said Gregorio De Haene, Chief Technology Officer at Sigma. “Our partnership with Onego Bio reflects our ambition to stay ahead of evolving consumer preferences by exploring innovative ingredients like non-animal egg protein. This collaboration allows us to further strengthen our sustainability journey while bringing new, future‑forward solutions to the table.”
As part of this agreement, Onego Bio and Sigma will conduct feasibility assessments, prototype development, and application trials in commercially relevant food. Early-stage evaluations of Bioalbumen® have shown promising results in both nutrition and functional performance against animal-based benchmarks.
“We are excited to collaborate with Sigma, a company that shares our vision for science-based innovation and a resilient food system,” said Maija Itkonen, CEO and Co-Founder of Onego Bio. “Bioalbumen® is a powerful tool to support ESG goals for global food manufacturers and strengthen product stability at a time when the egg industry is increasingly vulnerable to disease outbreaks and pricing volatility.”
This partnership underscores a shared vision for advancing food innovation and aligns with Sigma’s broader strategy to meet long-term sustainability goals, while exploring novel ingredient solutions that promote, healthy, nutritious, and delicious food.
In addition to this agreement, Andrea Nieto, Product Development Manager at Sigma, will join Onego Bio in a live cooking demo webinar in April 2026, offering an inside look at how Bioalbumen® performs in real product formulations and what early tests reveal about its commercial potential. This demo is part of Onego Bio’s The Power of Trichoderma reesei webinar series. To view previous sessions from this series, visit https://www.onego.bio/newsroom. To register for the upcoming session titled Strengthening Food System Resilience Through Ecosystem Building, visit https://shorturl.at/9HrV3.
About Sigma Foods
Sigma Foods, S.A.B. de C.V (“Sigma Foods”) is a leading multinational consumer packaged goods company that produces, markets, and distributes high-quality foods through a portfolio of over 100 brands, 16 of which generate Revenues between US $100 million and US $1 billion annually, each. The company's main categories include cold cuts, dry meats, cheese, and yogurt. Sigma Foods operates in 17 countries, divided into four regions: Mexico, Europe, the United States, and Latam, where it serves more than 640,000 points of sale in 3 channels: Traditional, Modern, and Foodservice. The company has over 47,000 employees and installed capacity in each region, including: 65 production plants, 191 distribution centers, and more than 8,000 vehicles. Sigma Foods shares are traded on the Mexican Stock Exchange and Latibex, the Latin American stock market of the Madrid Stock Exchange.
About Onego Bio
Onego Bio is a food ingredient company on a mission to create a more resilient food system through its product Bioalbumen®—a non-animal egg protein with an amino acid sequence identical to conventional ovalbumin. Made through precision fermentation, Bioalbumen® matches the taste, nutrition, and functionality of the main protein from traditional eggs with an environmental impact around 90% smaller. Its unmatched versatility makes it ideal across a wide range of applications while providing greater cost and supply stability for food manufacturers. Learn more at www.onego.bio.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260305756400/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sine kompetencer inden for cybersikkerhed gennem samarbejde med A3Sec5.3.2026 17:16:00 CET | Pressemeddelelse
Andersen Consulting styrker sine tilbud inden for cybersikkerhed og teknologisk transformation gennem en samarbejdsaftale med A3Sec, et firma, der specialiserer sig i datadrevet trusselsdetektion, hændelsesrespons og exposure management. Med hovedsæde i Spanien og kontorer i Mexico og Colombia har A3Sec mere end 14 års erfaring med at hjælpe offentlige og private organisationer inden for finans, telekommunikation, energi, den offentlige sektor og erhvervslivet med at sikre deres digitale aktiver. Virksomheden driver sit Security and Digital Surveillance Center® (CSVD®) døgnet rundt med et team på over 180 cybersikkerhedseksperter og betjener mere end 280 kunder verden over. Firmaet leverer integrerede cybersikkerhedstjenester, herunder managed detection and response, cybertelemetri, trusselsanalyse og krisestyring, og hjælper kunder med at styrke deres robusthed og omdanne risiko til en strategisk fordel, samtidig med at de effektivt håndterer eksponering og minimerer risiko. "Vores fo
Xsolla Agency Launches to Empower Creators Across Entertainment-Based Intellectual Property5.3.2026 16:23:00 CET | Press release
New Service Simplifies Access to Premium IP Licensing, Driving Discoverability, Player Engagement, and Revenue for Game Developers Xsolla, a global video game commerce company, today launched Xsolla Agency, a comprehensive service connecting game developers with premium entertainment-based intellectual property (IP). The integrated offering addresses critical challenges for game creators: access to world-class IP, global monetization capabilities, and the operational infrastructure needed to build sustainable businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305044119/en/ Graphic: Xsolla Xsolla Agency simplifies access to entertainment-based licenses through expert-led negotiations and industry relationships, offering affordable, monetization-focused deals structured for maximum ROI. Strategic IP partnerships increase discoverability, reduce user acquisition costs, and drive higher player spend through impactful
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures5.3.2026 16:00:00 CET | Press release
-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX--These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14 days), demonstrating the potential for JOURNAVX as a core element of opioid-free multimodal treatment for moderate-to-severe acute pain after aesthetic and reconstructive procedures. In contrast, the literature shows opioid-free rates of less than 10% with multimodal treatment without JOURNAVX. These dat
Ushio Completes Acquisition of OSRAM Entertainment and Industry Business5.3.2026 15:08:00 CET | Press release
Business to operate globally as Ushio Industry & Entertainment Ushio Inc. today announced the successful completion of the acquisition of the OSRAM Entertainment and Industry (ENI) business. As of March 2, 2026, the business officially operates as part of the Ushio Group under the name Ushio INE GmbH (hereinafter: Ushio Industry & Entertainment). This strategic acquisition strengthens Ushio’s global position in specialty lighting and expands its capabilities across entertainment, cinema projection, stage lighting, industrial applications, and high-performance professional solutions. The newly integrated organization combines Ushio’s established technology portfolio and global manufacturing strength with the long-standing expertise, customer relationships, and application knowledge of the former OSRAM Entertainment and Industry team. Marko Haas, General Manager of Business Division of Ushio Industry & Entertainment, commented: “This marks an important milestone for our business and our
Adaptive announces strategic investment from HSBC and Citi to fuel capital markets technology innovation5.3.2026 14:01:00 CET | Press release
Investment capitalizes on significant technological shifts in capital markets driven by cloud, open-source and AIFunding to scale Adaptive’s development of next-gen cloud-enabled front office solutions, centered around its Aeron® technology Adaptive, a leader in custom trading technology solutions, announces it has secured strategic investment from two prominent global financial institutions, Citi and HSBC. This funding is set to significantly accelerate Adaptive’s growth and product innovation roadmap. The strategic backing from HSBC and Citi underscores the collaboration between Adaptive and two of the world’s largest financial institutions on strategic initiatives to reshape capital markets technology. It will enable Adaptive to capitalize on significant technological disruption and meet the growing demand for client‑owned, differentiated and bespoke trading technology. Centered around Adaptive’s suite of Aeron®products, the funding allows the company to scale its delivery of high-p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom